The abstract is read at the publisher; the summary is JClub's.
CD266+ myofibroblasts in unresectable/recurrent/metastatic head and neck squamous cell carcinoma are linked to resistance to immunochemotherapy via PIEZO1-driven ECM stiffening and immune exclusion.
- Why it matters: Immunotherapy outcomes in U/R/M HNSCC are worse than in primary untreated resectable disease, and the stromal/immune changes during treatment are key to explaining resistance.
- What they did: Single-cell RNA sequencing of 42 pre- and posttreatment patient samples from a prospective immunochemotherapy trial (NCT05156970) identified CD266+ CAF, and PIEZO1 inhibition was tested mechanistically and in vivo.
- The result: PIEZO1 inhibition suppressed YAP activation and reduced FAK phosphorylation, mitigating CD266 myofibroblast matrix remodeling, and showed synergy with PD-1 blockade in HNSCC in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.